Australia Healthcare Diagnostics Market

Australia Healthcare Diagnostics Market
Analysis
A sample report on

This report presents a strategic analysis of the Australia Healthcare
Diagnostics Market and a forecast for its development in the medium
and long term. It provides a comprehensive overview of the market
value, dynamics, segmentation, main players, growth and demand
drivers, challenges & future outlook, etc. This is one of the most
comprehensive reports about the Australia Healthcare Diagnostics
Market, and offers unmatched value, accuracy, and expert insights.

3
A Sample Report on Australia Healthcare Diagnostics Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Healthcare Diagnostics Overview 12-25
1.1. Overview
1.2. Australia Overview
1.3. Economic Overview: Australia
1.4. Statistic at a glance
1.5. Healthcare Services Market in Australia
1.6. Healthcare Scenario in Australia
1.7. Health Insurance Coverage: Australia
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 26-31
2.1 Market size and forecasts (Excel and Methodology)
2.2. Market Segmentation

5
Table of Content
CONTENT PG. NO.
2.2.1. By Test
2.2.2. By Testing Method
2.2.3. By End User
3. Types of Clinical Diagnostics Test 32-36
3.1 Laboratory Test
3.2 Imaging Test
3.3 Point-Of-Care Testing
4. Market Dynamics 37-41
4.1. Market Growth Drivers
4.1.1. Increasing Prevalence of Health Morbidities like Cancer, Chronic & Infectious Diseases
4.1.2. Growing awareness about early detection & screening of diseases
4.1.3. Government initiatives and investments in increasing number of equipment in diagnostic
facility

6
Table of Content
CONTENT PG. NO.
4.2. Market Restraints
4.2.1. Delayed in Diagnosis
4.2.2. Shortage of Diagnosis Equipment
4.2.3. Data Privacy Concerns 42-47
5. Competitive Landscape
5.1. Key Company Profile
5.1.1. Australia Clinical Labs
6. Reimbursement Scenario 48-54
6.1. Reimbursement Regulation
6.2. Reimbursement Process for Diagnosis
6.3 Reimbursement Process – Medicare
6.4 Reimbursement Process – Medicaid

7
Table of Content
CONTENT PG. NO.
7. Methodology & Scope 55-62

Australia Healthcare Diagnostics Market Analysis
1. Healthcare Diagnostics Overview

9
1.1 Statistics at a Glance: Status of Healthcare Diagnostics in the World
Overview of Healthcare Diagnostics ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
$76.2 Bn
Was the market size of Global
Clinical Diagnostics in 2022
8.56%
Can be the exhibiting CAGR of
the Clinical Diagnostics Market
from 2022-2028
$7 Bn/year
Is the amount saved using the health apps by monitoring and diagnosing
health condition associated with diabetes prevention and care, asthma, and
cardiac and pulmonary rehabilitation
17-20%
Is the expected increase in
revenue of the diagnostic
companies
55%
Of the most downloaded
clinically rated apps are linked
to biosensors
Illustrative

10
1.1 Statistics at a Glance: The Status of Healthcare Diagnostics in the World
(continued)
Illustrative
North America
~ Market Size of
$XX Bn
Europe
~Revenue to reach
$XX Bn by 2027
Asia
-Fastest CAGR
Africa
~Market Size of
$XX Bn
Australia Market
~$xx Mn Market

11
1.2 Australia Overview
25.7 Mn
Is the population of
Australia, in 2021
38.5 years
Is the median age
in Australia, in
2022
$1.55 Tn
Is the Gross
Domestic Product
(GDP) in Australia in
2021
$8617
per capita was the
amount of national
health expenditures in
2021
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest
Illustrative

12
1.3 Economic Overview: Australia
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Australia, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Australia, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

13
1.4 Statistics at a Glance: Glance at Australia Healthcare Diagnostics Market
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Australia
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
$827 Mn
Was the market size of
Australia Clinical Diagnostics
Market in 2022
7.5%
Is the expected CAGR of the
Australia Clinical Diagnostics
Market for period of 2022-
2030
2,808
Is the number of medical and
diagnostic laboratory
companies are present in
Australia
42 days
Is the average waiting period
for CT scans in Australia
Illustrative

14
1.5 Healthcare Services in Australia
xx xx xx xx xx xx xx xx xx
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Australia Healthcare Services Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Healthcare Services market in Australia, which includes the market size, current
trends and other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
Illustrative

15
1.6 Healthcare Scenario in Australia
1. Universal Healthcare: Australia has a universal healthcare system known as Public. It provides Australians with access to subsidized
medical services, including visits to general practitioners, specialist consultations, and public hospital services.
2. Primary Healthcare: Primary healthcare plays a vital role in Australia's healthcare system. It involves general practitioners (GPs) who serve
as patients’ first point of contact. GPs provide preventive care, diagnose and treat common illnesses, and refer patients to specialists when
needed.
3. Public and Private Healthcare: Australia has a mix of public and private healthcare sectors. Public hospitals are funded by the government
and provide free or low-cost services to eligible patients. Private healthcare offers additional services and options for those who have private
health insurance.
4. Pharmaceutical Benefits Scheme (PBS): The PBS subsidizes the cost of prescription medications, making them more affordable for
Australians. Under this scheme, patients pay a reduced price for medications listed on the PBS schedule.
5. Aged Care Services: Australia has a well-developed aged care sector to cater to the needs of older adults. It includes residential aged care
facilities, home care services, and community-based programs.
6. Health Workforce: Australia has a well-trained and diverse healthcare workforce, including doctors, nurses, allied health professionals, and
specialists. The country also welcomes international healthcare professionals to address workforce needs.
Illustrative
Healthcare scenario in Australia is characterized by a robust system that aims to provide universal access to high-
quality healthcare services

16
1.6 Healthcare Scenario in Australia (continued)
7. Health Promotion and Prevention: Australia emphasizes health promotion and disease prevention initiatives. Various campaigns and
programs focus on promoting healthy lifestyles, disease screening, immunization, and early intervention.
8. Digital Health: The adoption of digital health technologies is increasing in Australia. Electronic health records, telehealth services, and
digital health platforms are being used to improve access to healthcare and enhance coordination of care.
Illustrative
Healthcare scenario in Australia is characterized by a robust system that aims to provide universal access to high-
quality healthcare services

17
1.6 Healthcare Scenario: Diagnostic Process Patient Journey
Patient
Physician
Laboratory Test/Imaging
Test/Molecular Diagnostic
Pathologist/Radiologist
Patient sees family
doctor or specialist
Pathologist/Radiologist produces
a report and sends it to referring
physician
Report contains summary of
findings, possible diagnoses,
and recommended next steps
Next Step
Based on the radiologist's report,
the referring physician decides on
the next steps for patient
Physician sends patient
for medical imaging
Results get sent to pathologist/
radiologist for review and analysis
Illustrative

18
1.7 Health Insurance Coverage: Australia
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Medicaid
Medicare
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed by Public (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
58,541 60,226 0.5
58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative

19
1.8 Budget of Australia Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Private $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Private 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

20
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

21
1.9 Mergers and Acquisitions (continued)
Latest Deals In Australia
Company Merger/acquisition Key Insights
Acquisition
▪ In 2019, Siemens Healthineers completed the acquisition
of Diagnostic Solutions, a specialized company in cancer
screening and diagnostic solutions
▪ Objective of this acquisition was to enhance Siemens
Healthineers' footprint in the diagnostics market
Merger
▪ In August 2023, Australian Clinical Labs (ACL) and
Healius revealed plans for a potential merger.
Illustrative

22
1.9 Mergers and Acquisitions (continued)
Latest Deals In Australia
Company Merger/acquisition Key Insights
Illustrative

2. Market Size and Forecasting

24
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Australia Healthcare Diagnostics Market Forecast, 2022-2030 (in
$Bn)
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the overall Healthcare
Insurance market in Australia, which
includes the market size, current trends
and other details related to the topic
detailed, and it will include data,
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Australia Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Australian Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Australia Market Size (Bn
$)
61 74 84 87 91 95 99 106
Illustrative

25
2.2 Snapshot of Healthcare Diagnostics Market Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Australia Healthcare Diagnostics Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Lipid Panel
Liver Panel
Laboratory
Imaging
Point-of-care
Patients
Healthcare Providers
By Test
Renal Panel
Complete Blood Count
Electrolyte Testing
Infectious Disease Testing
Others
By Testing Methods
Clinical Laboratory
Hospital & Healthcare institution
Others
Illustrative
By End-User

26
Australia Healthcare Diagnostics Market Share, By Test (2022)
Lipid Panel
Liver Panel
Renal Panel
Complete Blood
Count
Electrolyte
Testing
Infectious
Disease Testing
Others
▪ Lipid Panel market in Australia is a significant
component of the overall clinical diagnostics
treatment market
▪ It has the maximum market share in Australia
clinical diagnostics market with
approximately xx%
intended to provide you with a brief overview
of the kind of information and analysis that
will be presented in the final report
trends, and other relevant information related
to the topic or subject matter of interest
2.2.1 Market Segmentation: By Test
Illustrative

27
Australia Healthcare Diagnostics Market Share, By Testing
Methods (2022)
Laboratory
Imaging
Point-of-care
2.2.2 Market Segmentation: By Product
▪ Instruments clinical diagnostics market in
Australia is a significant component of the
overall clinical diagnostics market
▪ It has the maximum market share in Australia
clinical diagnostics market with
approximately xx%
Illustrative

28
Australia Healthcare Diagnostics Market Share, By End User
(2022)
Clinical
Laboratory
Hospital &
Healthcare
Institution
Healthcare
Providers
Other
Patient
2.2.3 Market Segmentation: By End User
▪ Hospital Laboratories have the maximum
market share in Australia clinical diagnostics
market with approximately xx%
Illustrative

3. Types of Healthcare Diagnostics Testing Methods

30
3.1 Laboratory Test
Top most commonly ordered laboratory tests in Australia
The data presented here includes over 51 commonly ordered laboratory tests by percentage in Australia (Appendix 3)
Complete blood count Creatinine
Thyroid stimulating hormone Electrolyte panel
Alanine amino-transferase Hemoglobin A1c
LDL cholesterol Ferritin
Urinalysis with microscopic Others
Community
Complete blood count Electrolyte panel
Creatinine Magnesium
Phosphate Scan with morphology
Urea Prothrombin time (INR)
Calcium Others
Inpatient
Complete blood count Chem panel 7
Creatinine Electrolyte panel
Liver panel Troponin-T
Prothrombin time (INR) Urinalysis with microscopic
Blood culture Others
Emergency
Illustrative

31
3.2 Imaging Test
▪ Imaging tests in Australia include: X-rays, CT (Computed Tomography) scans, MRI (Magnetic Resonance Imaging) scans
Ultrasound, PET (Positron Emission Tomography) scans, Nuclear imaging & Mammogram
▪ In 2022, it was estimated that 28,600 Canadian women will be diagnosed with breast cancer ultimately raising the demand
for Mammography Imaging as well as services
▪ In August 2022, through a collaboration with Synthesis Health, Pelican Narrows and two additional Peter Ballantyne Cree
Nation (PBCN) towns, Deschambault Lake and Southend, the first ultra portable X-ray equipment was installed in Australia
Imaging Test 2017 2020 2030
Computed Tomography Scan (CT) in Mn XX XX XX
Magnetic Resonance Imaging (MRI) in Mn
XX XX XX
Positron Emission Tomography (PET) in Mn XX XX XX
Number of diagnostics expected to be performed in Australia (in Mn)
Illustrative

32
Key Insights
3.3 Point-Of-Care Testing
POC Diagnostics Market Share, By Indication
Hematology Testing
Cardiometabolic Diseases
Others
Pregnancy & Infertility
Testing
Infectious Diseases
Blood Glucose Monitoring
▪ Increased prevalence of diabetes and cancer, the use of novel
point-of-care diagnostics, and the preference for at-home
glucose testing all contribute to the expansion of the blood
glucose monitoring market
▪ XX% of the population of Australia, or more than XX Mn
people, have diabetes, and after accounting for population
ageing over time, the prevalence has been rising at an
average rate of XX% each year
▪ Considerable risk of acquiring type 2 diabetes is also posed by
the XX% prevalence of prediabetes in Canadian adults
▪ On the other side, the category for infectious disorders is
expected to develop at the quickest rate
▪ Market segment for infectious diseases is anticipated to
expand significantly over the forecast period due to the rising
prevalence of various infectious disorders
Other*- Hyperthyroidism, Oxygen Testing, assessment for developing contrast-
induced nephropathy (CIN), Colorectal cancer screening, Dipstick urinalysis
Illustrative

4. Market Dynamics

34
4.1 Market growth drivers
▪ Incidence of diseases is increasing in Australia, In 2021, approximately
151,000 new instances of cancer were identified in Australia.
▪ Nearly half of Australians, spanning all age groups (46.6%), experienced
one or more chronic conditions, with nearly one in five individuals (18.6%)
grappling with two or more chronic health issues.
▪ This is driving the demand for clinical diagnostics treatments and creating
opportunities for growth in the clinical diagnostics market
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be presented
in the final report
▪ In order to obtain access to all of the information that you are seeking, you
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
4.1.1 Increasing Prevalence of Health Morbidities like Cancer, Chronic & Infectious Diseases. 46.6% of population
have at least 1 of 10 common chronic conditions in Australia
Incidence of Diseases in Australia
Illustrative

35
4.1 Market growth drivers (continued)
Top countries that are leveraging
technology in their fight against
healthcare diagnostics
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
4.1.2 Growing awareness about early detection & screening of diseases. The Australian government has established
nationwide screening initiatives for breast, cervical, and bowel cancers
▪ Primary goal of these screening programs is to enhance
public health outcomes by minimizing the impact of illness
and mortality associated with these cancers through early
detection and timely intervention
▪ QAAMS pathology program is designed to offer prompt on-
site diabetes testing specifically for Aboriginal and Torres
Strait Islander individuals residing in rural and remote areas
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

36
4.1 Market growth drivers (continued)
Fundings from government and other
organizations
4.1.3 Government initiatives and investments in increasing number and quality of equipment in diagnostic facility.
▪ Australia government provides significant support and
funding for clinical diagnostics research and treatment,
which is driving innovation and growth in the clinical
diagnostics market
▪ Albanese Government is allocating $XX Mnto support XX
projects focused on providing educational initiatives for
healthcare professionals and the public
▪ These programs aim to enhance awareness about the
appropriate utilization of medicines and diagnostic
technologies
▪ Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
Source Year Fund ($)
Replacing Outdated
Equipment
XX $ XX Mn
Lund disease
scanner
XX $ XX Mn
Digital health XX $ XX Mn
Albanese
Government
XX $ XX Mn
Illustrative

37
4.2 Market restraints
3.2.1 High cost & Delayed in
Diagnosis. 30% of Australian children
with rare disease waited for 5 or more
years for diagnosis
▪ Clinical diagnostics treatments can be
very expensive and can lead to
financial burden for patients and
healthcare systems
▪ Cost of clinical diagnostics treatment
varies depending on the type of
clinical diagnostics, stage of clinical
diagnostics, and treatment options
▪ Some common clinical diagnostics
treatments, such as chemotherapy
and radiation therapy, can cost tens of
thousands of dollars
3.2.2 Australia's clinical diagnostics
sector operates under rigorous
regulations, featuring strict standards
for the approval of products and
ongoing quality monitoring
▪ Requirements for clinical diagnostics
treatments can be very stringent,
which can slow down the approval
process and limit access to new
treatments
▪ Therapeutic Goods Administration
(TGA) is the regulatory authority
overseeing medical devices, including
in vitro diagnostic medical devices, in
Australia
▪ Manufacturers and sponsors of
medical devices are obligated to
adhere to the mandatory requirements
and fulfill ongoing responsibilities as
stipulated by the TGA
3.2.3 Data Privacy Concerns.
Approximately 75% of Australians
believe that data breaches pose one of
the most significant privacy threats
they encounter in the present day
▪ Medicare breach reported in October
2022 was among the most recent
incidents that profoundly impacted the
industry, revealing the sensitive data
of 9.7 Mn existing and former
customers
▪ Final report will be comprehensive
and detailed, and it will include data,
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative

5. Competitive Landscape

39
5.1 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let us know via email
1 Australian Clinical Labs
2 Healius Healthcare
3 Sonic Healthcare
4 Austech Medical Laboratories
5 Healthcscope Limited
6 AusDiagnostics
7 Abbott
8 Bio-Rad Laboratories, Inc
9 Roche
Siemens
Key Note:
10
Service Providers Manufacturers
Illustrative

40
5.1.1 Australian Clinical Labs (ACL)
Founded in: 2015
HQ: Sydney, Australia
Type: Private
Revenue: $995.6 Mn
Website: Australian Clinical Labs
▪ Australian Clinical Labs stands as a prominent private pathology
services provider in Australia, with 75 laboratories accredited by
NATA, offering essential diagnostic services
▪ Annually, our accredited laboratories conduct more than 12 million
tests, benefiting both healthcare professionals and individuals
within the local communities we serve
▪ As a leading entity in the field, Australian Clinical Labs plays a vital
role in delivering high-quality pathology services to clinicians and
patients across Australia
Solutions offered by ACL
➢ Diagnostics
➢ Pharmacogenetic Testing
➢ Hospital Services
➢ Courier Service
Routine pathology tests
Advanced molecular genetics
testing
Genetic carrier screening
Harmony NIPT & first trimester
screening
Pharmacogenomic Tests Allergy & immunology
Chemical pathology Cardiac testing services
Histopathology &
cytopathology
Veterinary pathology
Services Offered Recent Activity / Press Coverage
› Australian Clinical Labs (ACL) parent company Medlab faced a Quantum
hacking group cyber attack in February 2022, resulting in the theft of 86GB data
from over 200,000 people, including health, passport, and credit card details
› Geneseq Biosciences and Australian Clinical Labs have declared their
collaboration to introduce the inaugural non-invasive melanoma test to the
market, operating under the brand name Melaseq
Illustrative

41
5.1.1 Australian Clinical Labs(continued)
Major Brands Major Divisions
Subsidiaries
▪ Since 2008, Helix Pathology has been
providing specialized histopathology and
cytology testing services to the Gold
Coast region, spanning from the Northern
Gold Coast to Tweed Heads
▪ Southern Sun stands as the largest
specialized skin cancer laboratory in
Australia and holds the distinction of
being the initial commercial laboratory in
the country to incorporate digital
scanning into its operations
Illustrative

42
Company Name Type
Amount /
Duration
Year Key Pointers
Acquisition - May, 2021
▪ SunDoctors is a dedicated organization focused on diagnosing
and treating skin cancer through efficient, doctor-led procedures,
supported by top-notch facilities and equipment
Important Deals - Mergers and Acquisitions
Illustrative

43
63.3
70.3 70.9
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ $977.9 Mn was the revenue generated by
Australian Clinical Labs in 2022
▪ They are profitable in a wide range of laboratory
testing services including routine and specialty
tests in areas such as hematology, clinical
chemistry, immunology, molecular diagnostics
and genetics
▪ Revenue generated by Dynacare in 2020 reflects
the company's continued growth and success in
the healthcare industry
▪ In order to obtain access to all of the information
that you are seeking, you will need to purchase
the final report
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

44
5.1.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for clinical
diagnostics
Recent Activity / Press Coverage
Illustrative

45
5.1.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

46
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

47
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

6. Reimbursement Scenario

49
6.1 Reimbursement Regulation
The reimbursement scenario in the Australia Healthcare Diagnostics Market is
complex and can vary depending on the specific treatment, setting of care, and
insurance coverage. Here are some key points to consider:
▪ Medicare:
o Medicare is a federal health insurance program for people aged 65 and
older, as well as people with certain disabilities or health conditions
o Medicare covers many clinical diagnostics treatments, including
chemotherapy, radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Medicaid:
o Medicaid is a joint federal-state program that provides health insurance
for people with low incomes
o Medicaid coverage for clinical diagnostics treatments can vary by state,
and may be subject to limits on the amount and type of treatment
covered
▪ Private Insurance:
o Private insurance coverage for clinical diagnostics treatments can also
vary widely depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Medicare and Medicaid together provide
health insurance coverage for more than
4 in 10 Australians
Medicare
17%
Medicaid
and CHIP
21%
Employer-Sponsored
49%
Other Private
3%
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
Illustrative

50
6.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to clinical diagnostics treatments by requiring insurers
to cover certain preventive services, including clinical diagnostics screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as clinical diagnostics
▪ Reimbursement for New Treatments:
o Reimbursement for new clinical diagnostics treatments can be a complex and lengthy process, as insurers and government
programs often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

51
6.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (% of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

52
6.2 Reimbursement Process for Healthcare Diagnostics
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service,
the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

53
6.3 Reimbursement Process - Medicare
Medicare
Population Covered
▪ 100% population is covered under this scheme
▪ Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an
individuals Medicare account
Provider Restrictions/
Selection
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicare account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for clinical diagnostics up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

54
6.4 Reimbursement Process -Private
Private
Population Covered
▪ 38% population is covered under this scheme
▪ Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease
Provider Restrictions/
Selection
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicaid account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for clinical diagnostics up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

Life-sciences Market Research
Reports you can trust
www.insights10.com
We maintain an extensive database comprising
over 30,000 syndicated market research reports
within the pharmaceuticals and healthcare sector,
offering a global, regional, and country-level
perspective. Our services also include the provision
of customized research reports, meticulously
tailored to align with your specific requirements.

At Insights10, our extensive report
library spans a diverse range of
categories within the field of life
sciences.
Market Research
Reports across various
categories in healthcare
www.insights10.com
Digital
Health
Medical
Devices
Healthcare
Services
Rare
Diseases
Clinical
Trials
OTC &
Nutraceuticals
Pharma
(Diseases
& Drugs)

Click on the country to see the reports available
Global Coverage
North America
• US
• Canada
Latin America
• Brazil
• Argentina
• Mexico
• Ecuador
• Venezuela
• Senegal
Europe
• UK
• Germany
• France
• Italy
• Spain
• Russia
• Netherlands
• Sweden
• Romania
• Switzerland
• Poland
• Austria
• Ireland
• Norway
• Denmark
• Belgium
• Portugal
• Ukraine
• Bulgaria
• Finland
APAC
• India
• China
• South Korea
• Japan
• Australia
• Indonesia
• Hong Kong
• New Zealand
• Philippines
• Singapore
• Malaysia
• Thailand
• Vietnam
Middle East
• UAE
• Saudi Arabia
• Turkey
• Lebanon
• Kuwait
• Qatar
Africa
• Egypt
• Kenya
• South Africa
• Algeria
• Nigeria
• Libya
• Tanzania
• Morocco

What do our reports cover?
Market Overview
Growth Drivers & Growth Restraints
Epidemiology & Disease type
Market Size & Forecast
Competitive Landscape
Policy & Regulatory Landscape
Reimbursement Scenario
Recent Developments
Market Segmentation Factors Driving Future Growth
1
2
3
4
5
6
7
8
9
10

01 03
02 04 05
Define
precise
research
questions
Validate data
through primary
research
interviews
Gather data
through
secondary
research
Forecast
market size
and segment
analysis
Extract key
insights from
the research
findings
06
Compile &
present a
comprehensive
analytical report
Our Research Process

Bottom Up Approach
Analyze product or treatment pricing
and reimbursement strategies
Evaluate consumer or patient
demographics and numbers
Predict future market
growth or decline based
on key market trends &
dynamics
Find
final
market size
Top Down Approach
Examine the total healthcare expenditure in
the targeted disease or service domain.
Assess the proportion of spending
allocated to the specific product or
treatment category.
Predict future market
growth or decline
based on key market
trends & dynamics
Find
final
market
size
Data Triangulation & Data Validation

2022
2023-
2030
Report Attribute
Quantitative Units
Pricing and Purchase
Revenue in USD Million/Billion (Mn/Bn)
Our pricing and purchase options are adaptable to
suit the specific scope of work.
Details
Time Frame
Base
Year for
estimation
Forecast
Period
Report Scope
Delivery Timeline
Typically, the delivery of the final report falls within a
timeframe of 5 to 7 business days, but the exact
duration may vary depending on the project's scope.
Customization
We are pleased to offer you the option of
customizing the report to align with your specific
research requirements at no extra charge, provided
it falls within the defined scope of the project.

We have access to a multitude of highly
dependable data sources, supported by
years of experience that guide us in
discerning which sources are most reliable
and current for the specific information
needed.
Access to credible
data sources for
secondary research
www.insights10.com
Statistical
Databases
Annual
Reports
Trade
Publications
Online
Databases
Published
Research
Reports
White-
papers
Press
Releases

Reliable
Expert Verified
Realistic
Comprehensive
Easy to read
Our reports present data, which is
The report is prepared using a proven methodology and insightful
research
The report is prepared by a team of highly qualified & experienced
research analysts & vetted by our local associates
The report allows you to confidently make smarter business and
strategic decisions based on realistic findings
Covers everything you would need to know about the market
including market size, competitive analysis & much more
You do not have to be a market expert to understand what really is
happening on the market and how it works

Yearly Access
(Subscription)
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database Service
& KOL Mapping
Primary Research &
Interviews
Customized Market
Research Reports
Syndicated Market
Research Reports
Our Services

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market. We at
Insights10 are building the future of market research and
are committed to providing our clients with the right
intelligence and insights to make business decisions
quickly and efficiently.
Insights10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with
some of the best organizations in the world, generating
insights that provides substantial competitive advantage.”
Dr. Purav Gandhi, Founder & CEO
Click to watch Our Introductory Video here
CEO Speaks

Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of
experience in management
consulting in the Life Sciences
sector, and has worked with
diverse multinational firms in
the US, India, Middle East and
APAC regions. His primary area
of interest is Customer and
Market Strategy, Market
Access, and Digital Health with
special focus on emerging
markets like Africa, Middle East
and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research &
marketing professional with a
progressive experience of over 20
years in Life Sciences, Healthcare
services, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager
Leadership Team

… and many more
Pi-SM
GmbH
Our Clients

I've had the pleasure of availing Insights10’s services several times, and I've always
been impressed by their expertise, professionalism, and dedication to providing us with
the highest quality data and insights. Whether one is looking to launch a new product,
expand into a new market, or better understand one's target customers, Insights10
insures achieving the goals.
Their team of experts has a deep understanding of the healthcare industry, and they use
their knowledge to develop customized research solutions that meet the specific needs
of each client. I highly recommend Insights10 to anyone looking for a reliable and
experienced partner in healthcare market research. They're a valuable asset to any
company that wants to succeed in this dynamic sector.
Sid Panigrahy
Founder-CEO, MediGlobo Inc.,
(Healthcare - Group Company of Omi Holdings, Inc) Tampa, Florida (USA)
What our clients say

Dear Insights10 Team, I wanted to thank you all for the great work you conducted
producing the Kenya Medical and Diagnostic Laboratory Service Market Analysis. The
quality of the report was excellent, and you managed to complete it in record time. I was
also impressed by your quick turnaround on the topics discussed as a follow up after the
report's first version; you managed to gather the information required, plus a very good
analysis.
I will definitely consider working with you again if the opportunity arises, and will not
hesitate in recommending you to colleagues working in the field Thank you again for
your professionalism and team work. It was a pleasure working with you.
Lelio Marmora
CEO, The Management Lab, Geneva
Ex. Executive Director, UNITAID

Michael Blumberg Youssef Mallat
Wissem Menad
Dr. Robert Ryan
Co Founder GFAU Pty Ltd., Australia
Co Founder – Embi, Optimum Oral care, Australia
Opusline, A part of Accenture, Paris
Senior Manager Segment Marketing
Performance Health, London, UK
Chief Executive Officer, Innova Therapeutics, Inc., USA
We engaged INSIGHTS10 to assist us with our research requirements
for the Oral Care Market sector in Australia. We been very impressed
with the depth and quality of data and equally with the personal
service we experience from the management team on our account.
They understand our business, our challenges and our goals. There is
a real sense of partnership as we continue to work together.
The info you delivered on the European Patient
Support Market with a deep dive into countries
like Spain, Germany, Italy, France, UK and
Belgium, was very useful.
Insights10 has been a great resource for
getting a detailed report on the UK
Physiotherapy Market. Usually I had multiple
sources for getting global reports, but now I
can get in-depth country reports from
Insights10 which has been a game changer.
We were looking for very specific information regarding Abu Dhabi
Oncology Drugs Market. The insights provided by Insights10 is
fantastic and they just took less than three days to deliver the report.

Thank You
www.insights10.com
Email: insights@insights10.com
India: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

Australia Healthcare Diagnostics Market

Recommended

Recommended

More Related Content

Similar to Australia Healthcare Diagnostics Market

Similar to Australia Healthcare Diagnostics Market (20)

More from Insights10

More from Insights10 (19)

Recently uploaded

Recently uploaded (20)

Australia Healthcare Diagnostics Market